Raymond James & Associates
CLVS

Raymond James & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Raymond James & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,897
Closed -$98K – 4257
2021
Q1 		$98K Buy
+13,897
New +$93.2K ﹤0.01% 3782
2017
Q3 		– Sell
-7,581
Closed -$710K – 3513
2017
Q2 		$710K Buy
7,581
+3,102
+69% +$190K ﹤0.01% 2228
2017
Q1 		$285K Sell
4,479
-2,544
-36% -$155K ﹤0.01% 2723
2016
Q4 		$312K Buy
7,023
+773
+12% +$27.2K ﹤0.01% 2602
2016
Q3 		$225K Buy
+6,250
New +$134K ﹤0.01% 2795

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James & Associates's CLVS Position: Q2 2021 in Review

Raymond James & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 13,897 shares — an estimated $98K sold.

Raymond James & Associates first reported a position in CLVS in Q3 2016 and held it in 5 quarters. The position peaked at $710K in Q2 2017. 161 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Raymond James & Associates reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 13,897 Clovis Oncology, Inc. shares in Q2 2021, an estimated $98K.
  • Raymond James & Associates first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 5 quarters.
  • Raymond James & Associates's Clovis Oncology, Inc. position peaked at $710K in Q2 2017.
  • 161 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.